Judge Bryson Admits Royalty Calculation Based on Pre-Issuance Sales
On March 17, 2017, Judge Bryson denied defendant Eli Lilly & Company (“Lilly”) motion to exclude a portion of plaintiff Erfindergemeinschaft UroPep GbR (“UroPep”) damages analysis. Lilly argued that UroPep's analysis was faulty because it incorporated information about unpatented sales. The patent-in-suit is titled "Use of Phosphordiesterase Inhibitors in the Treatment of Prostatic Diseases" and issued on July 29, 2014. Lilly markets and sells a Phosphordiesterase Inhibitor called Cialis®. The U.S. Food and Drug Administration ("FDA") approved Cialis® to treat the signs and symptoms of benign prostatic hyperplasia ("BPH") on October 6, 2011. UroPep's economic expert calculated reasonable royalty damages using information about sales that took place before the patent-in-suit issued. The expert first computed Lilly's incremental revenues due to sales of Cialis® for the BPH indication by comparing sales of Lilly's Cialis® before ...